BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

971 related articles for article (PubMed ID: 17785360)

  • 1. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A; Patton L; Prontera O; Fanelli F; Ciampaglia W; Cognigni GE; Pagotto U; Pasquali R
    J Endocrinol Invest; 2011 Oct; 34(9):685-91. PubMed ID: 21586896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Source localization of androgen excess in adolescent girls.
    Ibáñez L; Potau N; Zampolli M; Prat N; Gussinyé M; Saenger P; Vicens-Calvet E; Carrascosa A
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1778-84. PubMed ID: 7989484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of relationship between 17-hydroxyprogesterone response to buserelin testing and hyperinsulinemia in polycystic ovary syndrome.
    Sahin Y; Ayata D; Keleştimur F
    Eur J Endocrinol; 1997 Apr; 136(4):410-5. PubMed ID: 9150702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.
    Rosenfield RL; Barnes RB; Ehrmann DA
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1686-92. PubMed ID: 7989476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
    Moghetti P; Castello R; Negri C; Tosi F; Perrone F; Caputo M; Zanolin E; Muggeo M
    J Clin Endocrinol Metab; 2000 Jan; 85(1):139-46. PubMed ID: 10634377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
    Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
    Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
    J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
    White D; Leigh A; Wilson C; Donaldson A; Franks S
    Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17-Hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: investigation of adrenal and ovarian cytochrome P450c17alpha dysregulation.
    Sahin Y; Keleştimur F
    Hum Reprod; 1997 May; 12(5):910-3. PubMed ID: 9194638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of buserelin testing in the evaluation of hirsute women.
    Ambrosi B; Re T; Passini E; Bochicchio D; Ferrario R
    J Endocrinol Invest; 1996 Apr; 19(4):204-9. PubMed ID: 8862498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens.
    Nestler JE; Jakubowicz DJ
    J Clin Endocrinol Metab; 1997 Dec; 82(12):4075-9. PubMed ID: 9398716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome.
    Tosi F; Negri C; Perrone F; Dorizzi R; Castello R; Bonora E; Moghetti P
    J Clin Endocrinol Metab; 2012 May; 97(5):1712-9. PubMed ID: 22419715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
    Yildiz BO; Yarali H; Oguz H; Bayraktar M
    J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of ovary and adrenal glands in hyperandrogenemia in patients with polycystic ovary syndrome.
    Kamel N; Tonyukuk V; Emral R; Corapçioğlu D; Baştemir M; Güllü S
    Exp Clin Endocrinol Diabetes; 2005 Feb; 113(2):115-21. PubMed ID: 15772904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hormonal phenotype of Nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency.
    Carbunaru G; Prasad P; Scoccia B; Shea P; Hopwood N; Ziai F; Chang YT; Myers SE; Mason JI; Pang S
    J Clin Endocrinol Metab; 2004 Feb; 89(2):783-94. PubMed ID: 14764797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
    Unlühizarci K; Keleştimur F; Bayram F; Sahin Y; Tutuş A
    Clin Endocrinol (Oxf); 1999 Aug; 51(2):231-6. PubMed ID: 10468995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.